动静脉结合术前化疗在进展期胃癌治疗中的应用

doi:10.16139/j.1007-9610.2023.01.05

摘要/Abstract

摘要：

围术期化疗是进展期胃癌综合治疗的重要组成部分。有别于常规的全身化疗，动静脉结合术前化疗在联合用药的基础上，根据药物作用特点，对给药方式进一步优化，在本中心已有20余年的临床应用和研究历史。本文将从理论基础、发展过程、治疗优势和临床研究进行介绍。通过回顾临床与基础研究，阐述其临床治疗效果和可能的作用机制。

关键词: 动静脉结合术前化疗, 进展期胃癌, 动脉介入化疗, 新辅助化疗

Abstract:

Perioperative chemotherapy has been an important part of the comprehensive treatment of advanced gastric cancer. Different from the conventional systemic chemotherapy, preoperative chemotherapy through intra-arterial combined with intra-venous further optimized delivery routes according to characteristics of different drugs on the basis of combination chemotherapy，which has been studied and practiced at our center for more than 20 years. In this review, we will introduce this chemotherapy from the aspects of theoretical basis, development process, treatment advantages, and clinical research. The clinical efficacy and possible treatment mechanisms will be discussed through looking back on both clinic and basic study.

Key words: Preoperative chemotherapy through intra-arterial combined with intra-venous administration, Advanced gastric cancer, Intra-arterial chemotherapy, Neoadjuvant chemotherapy

中图分类号:

R735.2

李国立, 郭飞龙. 动静脉结合术前化疗在进展期胃癌治疗中的应用[J]. 外科理论与实践, 2023, 28(01): 31-35.

LI Guoli, GUO Feilong. Preoperative chemotherapy through intra-arterial combined with intra-venous administration in treatment of advanced gastric cancer[J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 31-35.

参考文献 24

[13]	刘福坤. 进展期胃癌手术前后介入治疗[J]. 中国实用外科杂志, 2001, 21(7):403-404.
	LIU F K. Interventional treatment of advanced gastric cancer before and after operation[J]. Chin Pract Surg, 2001, 21(7):403-404.
[14]	李国立, 马龙, 相小松. 局部进展期胃癌动静脉结合的术前化疗——临床研究与存在的问题[J]. 外科理论与实践, 2019, 24(1):23-26.
	LI G L, MA L, XIANG X S. Clinical study on preoperative intra—arterial combined with intravenous chemotherapy for locally advanced gastric cancer and problems[J]. J Surg Concepts Pract, 2019, 24(1):23-26.
[15]	PREUSSER P, WILKE H, ACHTERRATH W, et al. Phase Ⅱ study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer[J]. J Clin Oncol, 1989, 7(9):1310-1317. doi: 10.1200/JCO.1989.7.9.1310 URL
[16]	ISHIHARA S, NAKAJIMA T, OHTA K, et al. Evaluation of effective neo-adjuvant chemotherapy (FLEP therapy) in the treatment of advanced gastric cancer[J]. Gan To Kagaku Ryoho, 1991, 18(11):1748-1752.
[17]	HE Q, MA L, LI Y, et al. A pilot study of an individua-lized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis[J]. BMC Gastroenterol, 2016, 16:8. doi: 10.1186/s12876-016-0422-7 URL
[18]	李国立, 鲍阳, 李宁, 等. 以淋巴结转移为主的晚期胃癌的FLEP法新辅助化疗[J]. 外科理论与实践, 2005, 10(5):425-428.
	LI G L, BAO Y, LI N, et al. Neoadjuvant chemotherapy (FLEP regimen) for gastric cancer with advanced lymph nodes metastasis[J]. J Surg Concepts Pract, 2005, 10(5):425-428.
[19]	李国立, 鲍阳, 姜军, 等. 动静脉联合给药的 FLEOX新辅助化疗加营养支持提高晚期胃癌可切除率[J]. 中华胃肠外科杂志, 2008, 11(5):428-431.
	LI G L, BAO Y, JIANG J, et al. Arteriovenous neoadjuvant FLEOX chemotherapy with nutritional support improves the resectable rate for advanced gastric cancer[J]. Chin J Gastrointest Surg, 2008, 11(5):428-431.
[20]	李国立, 范朝刚, 鲍扬, 等. 动静脉结合给药的FLEEOX方案对以淋巴结转移为主晚期胃癌的新辅助化疗[J]. 中华外科杂志, 2009, 47(15):1171-1174.
	LI G L, FAN Z G, BAO Y, et al. Neoadjuvant chemotherapy of FLEEOX regimen for unresectable gastric cancer resulting from advanced abdominal lymph nodes metastases[J]. Chin J Surg, 2009, 47(15):1171-1174.
[21]	ZHANG C, LI G, FAN C, et al. Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer[J]. World J Surg Oncol, 2012, 10:162. doi: 10.1186/1477-7819-10-162 pmid: 22891660
[22]	He Q, Li Y, Ma L, et al. Application of FLEEOX pre-operative chemotherapy via intra-arterial and intravenous administration in treatment of unresectable locally advanced gastric cancer[J]. J Gastrointest Surg, 2016, 20(8):1421-1427. doi: 10.1007/s11605-016-3153-8 URL
[23]	XIANG X S, SU Y, LI G L, et al. Phase Ⅱ study of pre-operative intra-arterial epirubicin, etoposide, and oxaliplatin combined with oral S-1 chemotherapy for the treatment of borrmann type 4 gastric cancer[J]. J Gastric Cancer, 2020, 20(4):395-407. doi: 10.5230/jgc.2020.20.e40 URL
[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68 (6): 394-424. doi: 10.3322/caac.v68.6 URL
[2]	YANG K, HU J K. Gastric cancer treatment: similarity and difference between China and Korea[J]. Transl Gastroenterol Hepatol, 2017, 2:36. doi: 10.21037/tgh.2017.04.02 pmid: 28529990
[3]	WANG F H, ZHANG X T, Li Y F, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021[J]. Cancer Commun (Lond), 2021, 41(8):747-795.
[4]	ZHANG X, LIANG H, Li Z, et al. Perioperative or post-operative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial[J]. Lancet Oncol, 2021, 22:1081-1092. doi: 10.1016/S1470-2045(21)00297-7 URL
[5]	KINOSHITA J, YAMAGUCHI T, MORIYAMA H, et al. Current status of conversion surgery for stage Ⅳ gastric cancer[J]. Surg Today, 2021, 51(11):1736-1754. doi: 10.1007/s00595-020-02222-0
[6]	KLOPP C T, ALFORD T C, BATEMAN J, et al. Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report[J]. Ann Surg, 1950, 132(4):811-832. pmid: 14771793
[7]	SULLIVAN R D, MILLER E, SIKES M P. Antimetabolite-metabolite combination cancer chemotherapy. Effects of intraarterial methotrexate-intramuscular Citrovorum factor therapy in human cancer[J]. Cancer, 1959, 12:1248-1262. pmid: 13835650
[8]	DUFF J K, SULLIVAN R D, MILLER E, et al. Antimetabolite-metabolite cancer chemotherapy using continuous intra-arterial methotrexate with intermittent intramuscular citrovorum factor. Method of therapy[J]. Cancer, 1961, 14:744-752. pmid: 13724783
[9]	ARIEL I M. Treatment of inoperable cancer by intra-arterial administration of mechlorethamine[J]. AMA Arch Surg, 1957, 74(4):516-524. pmid: 13410324
[10]	FUJIMOTO S, WATANABE Y, ENOMOTO K, et al. Studies on preoperative cancer chemotherapy. methods of preoperative intra-arterial infusion by the use of methotrexate or vinblastine[J]. Cancer, 1969, 24(3):433-441. pmid: 5343385
[11]	STEPHENS F O, HARKER G J, DICKINSON R T, et al. Preoperative basal chemotherapy in the management of cancer of the stomach: a preliminary report[J]. Aust N Z J Surg, 1979, 49(3):331-335. doi: 10.1111/ans.1979.49.issue-3 URL
[12]	SHCHEPOTIN I, EVANS S, CHORNY V, et al. Preoperative superselective intraarterial chemotherapy in the combined treatment of gastric-carcinoma[J]. Oncol Rep, 1995, 2(3):473-479. pmid: 21597762
[24]	XIANG X, GUO F, LI G, et al. Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: a retrospective real-world study[J]. Front Oncol, 2023, 12:1015962. doi: 10.3389/fonc.2022.1015962 URL